芪珍胶囊辅助治疗对乳腺癌T淋巴细胞亚群肿瘤标志物的影响及预后分析

Influence of Qizhen Capsule Adjuvant Therapy on T Lymphocyte Subsets Tumor Markers and Prognosis of Breast Cancer

目的:探究芪珍胶囊辅助治疗对乳腺癌T淋巴细胞亚群、肿瘤标志物及预后的影响。方法:选2019年1月至2021年1月我院收入并治疗的乳腺癌患者80例为研究对象,依据随机数字表采用简单随机分组方法将其分为对照组、观察组,每组40例,两组患者均接受EC化疗干预方案(环磷酰胺+阿霉素+氟尿嘧啶),观察组在此基础上联合芪珍胶囊口服治疗,两组患者均连续治疗6周。比较两组患者血常规情况、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))、肿瘤标志物指标[癌胚抗原(CEA)、糖类抗原153(CA153)、癌抗原125(CA125)]水平,截至随访2023年2月28日,分析两组患者中位无病生存期差异。结果:治疗前,两组患者红细胞、白细胞、血小板比较无显著差异(P>0.05)。治疗后,观察组白细胞、血小板治疗前后差值大于对照组(P<0.05)。治疗前,两组患者CD3^(+)、CD4^(+)、CD8^(+)比较无显著差异(P>0.05)。治疗后,观察组CD3^(+)、CD4^(+)治疗前后差值大于对照组(P<0.05)。治疗前,两组患者CEA、CA153、CA125比较无显著差异(P>0.05)。治疗后,两组CEA、CA153、CA125均降低,且观察组CEA、CA153、CA125治疗前后差值大于对照组(P<0.05)。截至随访2023年2月28日,观察组病情复发转移4例,对照组病情复发转移11例,与对照组相比,观察组无病生存期更高,生存优势更明显(χ^(2)=7.195,P=0.007)。两组患者治疗不良反应发生率比较无显著差异(P>0.05)。结论:芪珍胶囊辅助治疗可改善乳腺癌患者T淋巴细胞亚群、肿瘤标志物及术后生存情况,且用药安全性有一定保障。

Objective:To explore the effect of Qizhen capsule on T lymphocyte subsets,tumor markers and prognosis of breast cancer.Methods:Eighty patients with breast cancer who received treatment at our hospital from January 2019 to January 2021 were selected for this study.They were randomly divided into a control group and an observation group,with 40 patients in each group.Both groups received the EC chemotherapy intervention(cyclophosphamide+doxorubicin+fluorouracil).Additionally,the observation group received Qizhen capsule as oral treatment.Both groups were treated continuously for 6 weeks.The study compared the blood routine status,T lymphocyte subpopulations(CD3^(+),CD4^(+),CD8^(+)),and tumor marker indicators(carcinoembryonic antigen(CEA),carbohydrate antigen 153(CA153),and cancer antigen 125(CA125)levels between the two groups.As of the follow-up on February 28,2023,the study analyzed the difference in median survival time between the two groups.Results:Before treatment,there were no significant differences in red blood cells,white blood cells,and platelets between the two groups(P>0.05).After treatment,the difference in white blood cell and platelet counts before and after treatment in the observation group was greater than in the control group(P<0.05).Before treatment,there were no significant differences in CD3^(+),CD4^(+),and CD8^(+)between the two groups(P>0.05).After treatment,the difference in CD3^(+)and CD4^(+)before and after treatment in the observation group was greater than in the control group(P<0.05).Before treatment,there were no significant differences in CEA,CA153,and CA125 between the two groups(P>0.05).After treatment,CEA,CA153,and CA125 were decreased in both groups,with the difference in CEA,CA153,and CA125 before and after treatment in the observation group being greater than in the control group(P<0.05).As of February 28,2023,4 patients in the observation group experienced disease recurrence and metastasis,while 11 patients in the control group experienced recurrence and metastasis.Compared with the control group,the observation group had a higher disease-free survival rate,and the survival advantage was more pronounced(χ^(2)=7.195,P=0.007).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Adjuvant treatment with Qizhen capsule can improve the T lymphocyte subsets,tumor markers,and postoperative survival of breast cancer patients,and the treatment is safe.